![MCD-associated genetic alterations promote DLBCL in vivo. (A) Spleen image and histologic analysis of 8-month-old Myd88/Cd79b/BCL2 or Myd88/Cd79b/Prdm1/BCL2 full BM chimeras. Sections were stained with hematoxylin and eosin (H&E) or for IgD and GL7, CD35, B220, CD138, or Ki-67. Scale bar is 1 cm in spleen images, 500 μM in low-power H&E and immunohistochemistry images, and 20 μm in high-power H&E (H&E [HPF]). Additional examples of Myd88/Cd79b/BCL2 or Myd88/Cd79b/Prdm1/BCL2 animals are shown in supplemental Figures 4 and 5, respectively. (B) Frequency of lymphoid hyperplasia or DLBCL in 6- to 8-month-old Myd88/Cd79b/BCL2 or Myd88/Cd79b/Prdm1/BCL2 full BM chimeras. (C) VH usage from repertoire sequencing of sorted GCBs or MBCs from tumor-bearing Myd88/Cd79b/Prdm1/BCL2 animals. (D) V-region mutation frequency per read of monoclonal outgrowths in GCBs of tumor-bearing Myd88/Cd79b/Prdm1/BCL2 animals. Dominant CDR3 peptide sequence of monoclonal outgrowth is indicated.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/140/10/10.1182_blood.2022015926/3/bloodbld2022015926f6b.png?Expires=1723188357&Signature=Xf3im6Eq-CH5k~Pssdak3aLN6l3DdmHRn5g12c28GRM4EMIxChmI1J9xwN~~DkG8Nw4UGGYO6iTNFEGgR91MXpRkdMTR1Js1RJkKamN~wc1pO4G-RMEMSf9jPcRJPqWmqdx6rBpK-y8xlAmXOnNloN3ulsPsYbGbS8BukijOUCcd5sHNKbbG67TN7aThbLP4FAwE1VWHXY4BJ50skLpL0G6ApqQua0VcdsD2bisUB02PKffF3QsvmJMeim9t1rzNitRCUchMT06oSrM3xeciQW-SJgfHuTHVujO-YdxMqikwCTtFTP4EGOUF-BCaR6kG3kbrJS7NJ7x~Xv0SAmv4IQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
MCD-associated genetic alterations promote DLBCL in vivo. (A) Spleen image and histologic analysis of 8-month-old Myd88/Cd79b/BCL2 or Myd88/Cd79b/Prdm1/BCL2 full BM chimeras. Sections were stained with hematoxylin and eosin (H&E) or for IgD and GL7, CD35, B220, CD138, or Ki-67. Scale bar is 1 cm in spleen images, 500 μM in low-power H&E and immunohistochemistry images, and 20 μm in high-power H&E (H&E [HPF]). Additional examples of Myd88/Cd79b/BCL2 or Myd88/Cd79b/Prdm1/BCL2 animals are shown in supplemental Figures 4 and 5, respectively. (B) Frequency of lymphoid hyperplasia or DLBCL in 6- to 8-month-old Myd88/Cd79b/BCL2 or Myd88/Cd79b/Prdm1/BCL2 full BM chimeras. (C) VH usage from repertoire sequencing of sorted GCBs or MBCs from tumor-bearing Myd88/Cd79b/Prdm1/BCL2 animals. (D) V-region mutation frequency per read of monoclonal outgrowths in GCBs of tumor-bearing Myd88/Cd79b/Prdm1/BCL2 animals. Dominant CDR3 peptide sequence of monoclonal outgrowth is indicated.